Abstract 155P
Background
Circulating tumor cells (CTCs) are cells of epithelial origin from clones of the primary tumor, located in the G0 phase and found in the peripheral blood of patients with various forms of solid cancer. Currently, CTCs are found in breast cancer, prostate cancer, colorectal cancer, and their number is used as an independent prognostic factor. The detection of CTCs in various tumors can help in the study of the process of metastasis and the biology of tumor growth. The aim of the work is to establish the presence and frequency of CTCs in the peripheral blood of patients with cancer in the bladder.
Methods
41 peripheral blood samples from patients with verified bladder cancer of stage III-IV were analyzed. The blood was taken into vacuum tubes with anticoagulant. The selection of the CTC on the density gradient. From the obtained material, 2 cytological preparations were prepared on the cytocentrifuge of Hospitex diagnostics (Italy) and stained according to Romanovsky. Calculation of the CTC at the light-optical level using a Zeiss Primo Star microscope (Germany). The final result was the total number of detected CTCs. The control group consisted of peripheral blood samples from 10 patients without cancer.
Results
CTCs were detected in 46.3% of cases (19 samples) in the amount of 1-14 cells. In the morphological structure of primary tumors, according to the results of histological examination, the samples were divided as follows: squamous cell carcinoma – 1, adenocarcinoma (metastasis of cervical cancer) – 1, urothelial carcinoma – 17. The calculation of the CTC by morphological forms of the tumor showed that 4-6 cells were detected in squamous cell carcinoma, 6 cells in adenocarcinoma, and 2 - 14 cells in urothelial carcinoma (2-4 cells in the II st., 7-14 cells in the IIII st.; Xsr=2.43). In the blood samples of the control patients, CTCs were also not detected.
Conclusions
The presence of CTC in the peripheral blood of patients with bladder cancer was detected in 46.3% of cases and has differences depending on the morphological form of the tumor, which requires further study. The largest number of CTCs in our study was revealed in the transitional cell (urothelial) morphological form of cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides
151P - Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Presenter: Alison Hiong
Session: Poster viewing 03
152P - An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Presenter: Liqun Zhou
Session: Poster viewing 03
153P - Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Presenter: Tiago Padua
Session: Poster viewing 03
154P - Can urine cytology predict variants of bladder cancer?
Presenter: Hikaru Mikami
Session: Poster viewing 03
156P - The association between response to enfortumab vedotin therapy and primary tumor location in Japanese urothelial carcinoma patients
Presenter: Nozomi Hayakawa
Session: Poster viewing 03
163P - Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country
Presenter: Manuprasad Avaronnan
Session: Poster viewing 03
164P - F-18 PSMA-PET/CT-guided percutaneous prostate biopsy
Presenter: Rajender Kumar
Session: Poster viewing 03
165P - Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Presenter: Richard Kelly
Session: Poster viewing 03